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Abstract
Thiazolidinedione (TZD) insulin sensitizers have the potential to effectively treat a number of human diseases, however the
currently available agents have dose-limiting side effects that are mediated via activation of the transcription factor PPARc.
We have recently shown PPARc-independent actions of TZD insulin sensitizers, but the molecular target of these molecules
remained to be identified. Here we use a photo-catalyzable drug analog probe and mass spectrometry-based proteomics to
identify a previously uncharacterized mitochondrial complex that specifically recognizes TZDs. These studies identify two
well-conserved proteins previously known as brain protein 44 (BRP44) and BRP44 Like (BRP44L), which recently have been
renamed Mpc2 and Mpc1 to signify their function as a mitochondrial pyruvate carrier complex. Knockdown of Mpc1 or
Mpc2 in Drosophila melanogaster or pre-incubation with UK5099, an inhibitor of pyruvate transport, blocks the crosslinking
of mitochondrial membranes by the TZD probe. Knockdown of these proteins in Drosophila also led to increased
hemolymph glucose and blocked drug action. In isolated brown adipose tissue (BAT) cells, MSDC-0602, a PPARc-sparing
TZD, altered the incorporation of 13C-labeled carbon from glucose into acetyl CoA. These results identify Mpc1 and Mpc2 as
components of the mitochondrial target of TZDs (mTOT) and suggest that understanding the modulation of this complex,
which appears to regulate pyruvate entry into the mitochondria, may provide a viable target for insulin sensitizing
pharmacology.
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Introduction
Diabetes is an undertreated epidemic with an estimated 340
million diabetic persons world-wide and rapidly increasing
incidence throughout the developed and developing world [1].
Thiazolidinedione (TZD) insulin sensitizers have proven to be
effective therapeutic agents for treating a root cause of diabetes,
namely insulin resistance, and also have been shown to preserve
the function of the pancreatic b-cells, thus preventing progression
of pre-diabetic patients to frank disease [2,3]. However, in spite of
considerable effort, no regulatory approvals of new insulin
sensitizing agents have occurred over the past decade [4,5].
TZD pharmacology has generally been thought to require direct
activation of the nuclear transcription factor PPARc and, since it is
now generally accepted that activation of PPARc drives the side
effects of this class of agents (e.g., increased adiposity, volume
expansion, bone loss and congestive heart failure), there has been
no clear path forward to create new, more useful insulin sensitizers
[4]. Recently, Chen et al. have shown that TZD analogs that do
not bind or activate PPARc at physiologic concentrations have a
very similar insulin sensitizing pharmacology as produced by
rosiglitazone and pioglitazone in obese rodent models [6].
Moreover, TZDs also exerted insulin-sensitizing effects in isolated
hepatocytes that were completely independent of PPARc as shown
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by using hepatocytes from liver-specific PPARc knockout mice [6].
PPARc-sparing TZDs are now in Phase II clinical trials and a
prototype compound has been shown to lower glucose to the same
extent as pioglitazone in diabetic patients with reduced side effects
associated with activation of PPARc [7]. These findings suggest
that other mechanisms through which insulin sensitizers signal are
involved in their anti-diabetic pharmacology. The discovery of
novel insulin sensitizing agents would be facilitated if an alternate
TZD target could be identified and its biological function
established.
Numerous investigators have suggested that TZDs may have
important effects on mitochondrial function and/or biogenesis
(reviewed in [8]). Indeed, we showed several years ago that a
mitochondrial binding site for TZDs existed and we have
hypothesized that this may be important for the efficacy of this
class of drug [9]. We have designed a photo-catalyzable affinity
probe based on the structure of pioglitazone. This technique
provides a molecular tool that once selectively bound to its site of
action, can be covalently attached (crosslinked) to the site.
Demonstration of specificity is by selective competition prior to
the photo-activation of the probe [10]. We have employed this
technique along with mass spectrometry-based proteomics to
identify BRP44, a protein in the inner mitochondrial membrane
that is selectively crosslinked by this probe. BRP44 is an
evolutionarily-conserved protein and crosslinking studies of the
BRP44 ortholog in Drosophila revealed the presence of a second
related protein, BRP44 Like, which is also required for the
crosslinking by TZDs. Immunoprecipitation studies suggest that
both of these proteins form a multi-subunit complex that could
provide a new target for designing insulin sensitizers. Importantly,
two recent publications have independently demonstrated that
these same proteins, which have been renamed, Mpc1 and Mpc2
(BRP44 Like and BRP44, respectively), are key components of the
mitochondrial pyruvate carrier complex [11,12], placing these
proteins and the mitochondrial action of the insulin sensitizers at a
critical nodal point of metabolism.
Materials and Methods
Materials
The photoaffinity crosslinker and all TZDs were synthesized at
Kalexsyn (Kalamazoo, MI). The photoaffinity crosslinker was
iodinated with carrier-free 125I (Perkin-Elmer) using Iodogen
(Pierce), purified on a C18 column and stored in the dark at220uC
as previously described [9].
Membrane isolation and drug analog photoaffinity
crosslinking
All animal handling took place at Western Michigan University.
Tissue collection was carried out following carbon dioxide
asphyxiation and exsanguination out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Research Council. The
protocol was approved by the Institutional Animal Care and Use
Committee of Western Michigan University (Animal Use Protocol
Number: 10-01-02). Crude mitochondrial membranes were
prepared by differential centrifugation of homogenized mouse
tissues followed by photoaffinity crosslinking as previously
described [9]. Mouse liver mitochondrial fractions were prepared
as previously described [13] by treating with 0.15 mg digitonin/
mg of crude mitochondria in fractionation buffer (FB: 250 mM
sucrose, 10 mM Tris, pH 8, and Roche complete protease
inhibitor cocktail). Separation of the soluble outer membrane
and inner membrane space from the mitoplast pellet was
accomplished by centrifugation at 95006 g. Resulting mitoplasts
were treated with 0.5 mg Lubrol/mg protein in FB on ice for
15 minutes. The lubrol treated samples were placed on top of a 3
step gradient of 51%, 37% and 23% sucrose in 20 mM Na2PO4,
pH 7.4 containing protease inhibitors and centrifuged at
100,0006 g in a Beckman SW 32Ti rotor. Following centrifuga-
tion the matrix fraction was removed from the top gradient and
the inner membrane fractions were collected from the 51 and 37%
interfaces. Crosslinked material was separated by either SDS-
PAGE and then evaluated by Western blotting or initially by Blue
Native gel separation followed by a second dimension separation
on SDS-PAGE. The gels were dried and exposed to X-ray film to
identify the 125I-labled proteins. In some cases the crosslinking was
carried out in tissues from mitoNEET null mice [14].
Identification of proteins by proteomics
Crosslinked liver mitochondrial samples (20,0006 g) were
solubilized in 1% n-Dodecyl b-D-Maltopyranoside (DMM) and
ATP synthase related peptides were removed by immunoprecip-
itation before separation of the enriched sample by Blue Native
electrophoresis. The first dimension Blue Native gels were then
further resolved by SDS-PAGE to identify the specifically
crosslinked proteins, which were located by the satellite silver
stained patterns. Specifically crosslinked bands were cut from the
gel, reduced, alkylated, and trypsin digested in situ and subjected
to nanoLC-MS/MS [9]. Samples were concentrated and desalted
using on-line trapping then separated on a 75 mm610 cm BEH
column (Waters) using a nanoAcquity UPLC system coupled to a
Q-Tof Premier mass spectrometer. Data for protein identification
was acquired in MS‘E mode and searched against a NCBI and
SwissProt databases using Waters Proteinlynx Global Server
software v2.4.
Generation of antibodies and Western blotting
Rabbit antibodies were prepared against synthetic peptides
AYHYHQSQEKLKQEQQQPAV and SSTAVQPPPPVPPPPP-
SAVP for GC9399 and TNATAQSIQGLRFLHYNYGS and
SIRRAMSTTASKEWRDYFMS for CG14290 Drosophila se-
quences, respectively. Rabbit antibodies were prepared against
KLRPLYNHPAGPRTVFFWA of the mammalian sequence of
BRP44. BRP44L antibodies were obtained from Sigma. UCP1
antibodies were obtained from Abcam. Antibodies to the His-Tag
were obtained from Cell Signaling.
Expression of C-terminal extended BRP44
HEK293 cells were plated twenty-four hours prior to transfec-
tion in 6-well plates at 66105 cells/well in 2 mls/well antibiotic
free DMEM (Gibco 11965) supplemented with 10% Fetal Bovine
Serum (Gibco 16000), 1:100 MEM Non-Essential Amino Acids
(Gibco 11140), 1:100 Sodium Pyruvate (Gibco 11360) and 1:100
GlutaMAX (Gibco 35050) or in 100 mm dishes at 3.56106 cells
each in 10 mls. Plasmid DNA for transfection was purified using
the Clontech Nucleobond PC 500 kit (740574.25). Cells were
transfected using Lipofectamine 2000 Transfection Reagent
(Invitrogen 11668) at a 1:1 ratio of DNA (mg) to Lipofectamine
(ml) following Invitrogen’s suggested transfection protocol. Com-
plexes were formed in Opti-MEM I Reduced Serum Medium
(Gibco 11058-021) by diluting the appropriate amounts of DNA
and Lipofectamine separately into Opti-MEM I, incubating at
room temperature for 5 minutes, combining DNA dilutions with
Opti-MEM I dilutions and incubating another 20 minutes at room
temperature before adding transfection complexes dropwise to
wells and plates. Plating medium was not removed or exchanged
prior to transfection. The 6-well dishes were transfected using 5 mg
mTOT, New Target for Insulin Sensitizers
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of DNA and 5 ml Lipofectamine in 500 ml Opti-MEM I per well.
The 100 mm plates were transfected using 30 mg DNA and 30 ml
Lipofectamine in 3 mls Optim-MEM I per plate. The medium
was not replaced after transfection.
Drosophila studies
D. melanogaster w1118 strain was used for initial crosslinking
experiments. 3rd instar larvae and 3–4 days old flies were
collected. Larvae were washed in PBST. Tissues were processed,
and crosslinked as described above. Ubiquitous GAL4 driver y1
w*; P{Act5C-GAL4}17bFO1/TM6B, Tb1 (stock 3954) was obtained
from Bloomington Drosophila Stock Center. RNAi knock-down
lines targeting CG9399: w1118; P{GD4636}v13788 (stock v13788),
w1118; P{GD4636}v13789 (stock v13789); targeting CG9396
P{KK112662}VIE-260B (stock v104068); targeting CG32832
w1118; P{GD15967}v47810 (stock v44810), w1118;
P{GD15967}v47811/TM3 (stock v47811), P{KK113045}VIE-
260B (stock v102996); targeting CG14290 w1118;
P{GD3944}v15858 (stock v15858), P{KK102734}VIE-260B (stock
v103829); targeting CG16790 w1118; P{GD8781}v19160 (stock
v19160), P{KK107622}VIE-260B (stock v104333); and parental
strains v60000, and v60100 were obtained from Vienna
Drosophila Resource Center. Act-GAL4 driver was crossed to
RNAi construct carrying lines; progeny not carrying a balancer
chromosome was used for assays. Progeny (non-balanced) from the
cross between Act-GAL4 and corresponding parental line (60000
for GD lines and 60100 for KK lines) served as the control.
Flies were raised on semi-defined media (BDRC recipe).
Normal (Low) Sugar media contained 0.15 M sucrose. High
Sugar media had 0.75 M sucrose. Fly eggs were laid on the media
surface and hatching larvae were feeding the media of choice.
Eclosed adult flies (females) were transferred to vials with fresh
media within 24 h and aged for 7 days. Hemolymph glucose
measurements were performed as follows: adult female flies were
collected and punctured in the thorax with 25G syringe needle
and hemolymph was collected by centrifugation at 4,5006 g for
1 min. Samples were processed using Infinity glucose (Ox) reagent
(Thermo Scientific) according to manufacturer instructions. Full
genome expression arrays were obtained from Agilent. Slides
hybridization, reading, and basic statistical analysis were done at
MOGene (St Louis). Three biological replicas were obtained for
each experimental condition. Insulin-stimulated increase in pAKT
was performed as previously described [15]. Antibodies to AKT
and phosphor AKT (Ser505 homologous to human Ser473) were
from Cell Signaling.
Brown adipose progenitor cell differentiation assay
Brown adipose progenitor cells were isolated from the
interscapular pad of CD1 mice (Charles River) and cultured in
35 mm dishes according to the method of Petrovic et al. [16].
When the progenitor cells reached 90% confluence, differentiation
was initiated by treating the cells for 6 days with increasing
concentrations of TZDs or non-TZDS in DMEM containing
25 nM insulin and 10% FBS. UCP1 Western analysis was
conducted on cell lysates followed by densitometry on the
immunoreactive bands using Image J software.
13C Glucose Flux in primary brown adipose cells
Brown adipose progenitor cells were isolated as described
above. When the progenitor cells had expanded to 90%
confluence, differentiation was initiated by treating the cells for
48 hours with 1 mM MSDC-0160 in DMEM containing 25 nM
insulin and 10% FBS. The cells were then switched to DMEM
containing 25 nM insulin and 10% FBS with no drug for
96 hours. Flux was conducted on the differentiated cells by
pretreating for 2 hours in DMEM containing 5 mM glucose, 10%
FBS, 25 nM insulin and increasing concentrations of drug. The
15 minute flux experiments were initiated by removing the
DMEM, rinsing 1X with serum free DMEM and adding KRHB
(Krebs Ringer-HEPES Buffer) with 5 mM 13C-glucose (U-13C;
Cambridge Isotope Laboratories, Inc.), 25 nM insulin and drug.
The flux reaction was quenched by rinsing once with ice cold PBS,
once with ice cold water, and extracting with dry-ice chilled
methanol:chloroform as previously described [17].
LC-MS analysis of Acetyl CoA
Metabolomic analysis was performed using a Waters quadru-
pole time-of-flight (Qtof Premier) mass spectrometer mode
coupled to a Waters nanoAcquity UPLC. TCA cycle intermedi-
ates were separated using ion pairing reverse-phase chromatogra-
phy with a Waters BEH C-18 column (1.7 mm particle, 200 mm ID
610 cm length) and detected in the negative ion mode. The
mobile phase A was 10 mM tributylamine, 15 mM acetic acid in
97:3 water:methanol and mobile phase B was methanol. The flow
rate was 2 mL/min and the gradient was 0 min 0.5% B; 2.5 min
0.5% B; 19 min 95% B; 23 min 95% B; 26 min 0.5% B. Waters
Masslynx software was used to collect centroid, lockmass corrected
data. Entry of 13C was measured by comparing the ratio of
resolved isotopes of acetyl-CoA. Data were analyzed using Waters
Quanlynx software to determine the relative abundance of selected
ions.
Numerical data are presented as mean and standard error and
statistical comparison have been made by an unpaired, two-tailed
t-test to derive p values shown.
Results
Identification of a mitochondrial protein crosslinked
selectively by the TZD photoprobe
Incubation of the photoprobe, MSDC-1101, with mouse liver
mitochondrial membranes followed by photoactivation revealed a
,14 kDa radiolabeled band on the film (Figure 1A, see arrow,
lane 1). The addition of active TZDs such as MSDC-0160 and
MSDC-0602 before photoactivation inhibited crosslinking (lanes 2
and 3). In contrast, the addition of a TZD analog in which a
methyl group has been incorporated on the thiazolidine ring
nitrogen (MSDC-1473), resulted in no inhibition of crosslinking
(Figure 1A, lane 4). Unlike the other analogs, MSDC-1473 is
inactive in cellular assays, such as the activation of UCP1
expression in brown adipocyte precursor cells (Figure 1B). The
specificity of these competitive interactions for crosslinking versus
the activity in cells suggests that this mitochondrial protein could
be an important drug target.
Earlier efforts to identify the crosslinked protein suggested that it
was mitoNEET, a protein in the outer mitochondrial membrane
[8,14]. However, we now show that probe crosslinking of
mitochondrial membranes was not reduced in the complete
absence of mitoNEET protein in liver (or muscle, not shown) from
mitoNEET null mice (Figure 1C). Moreover, the crosslinked
protein was localized to the inner mitochondrial membrane
(Figure 1D) while mitoNEET is an outer mitochondrial membrane
protein [14].
The radiolabeled protein was successfully purified by a three
step approach involving solubilization and immunoprecipitation to
remove ATP synthase and related binding proteins. This was
followed by Blue Native gel electrophoresis in which the cross-
linked protein ran as a,150 kDa complex (Figure 2A) from which
a second dimension SDS-PAGE produced a single, selectively
mTOT, New Target for Insulin Sensitizers
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radiolabeled protein (final gel products are shown in Figure 2B).
The silver stain of the gel from a sample prepared in the absence of
competing analog is shown on the left and one from a sample with
the competing analog is shown on the right. Beneath each silver
stained gel is the image from the X-ray film from the sample. The
position of the specifically crosslinked protein is shown by the
yellow arrow on the X-ray image and the silver stained gel.
Figure 2C shows an enlarged region of interest on the silver
stained gels. The specific radiolabeled regions overlay two silver-
stained spots (spots 1 and 2) and a third area of the gel (spot 3) that
did not stain with silver is marked by the arrows. These areas were
cut from the gels and subjected to trypsin digestion and MS/MS
analysis.
All three gel slices analyzed by mass spectrometry identified 2–4
tryptic peptides from BRP44 (Q9D023) (Figure 2D). Several spots
from the gel also contained some tryptic peptides of microsomal
glutathione S transferase, however this protein could be com-
pletely removed from the solubilized crosslinked sample on a
glutathione column without trapping the labeled protein (not
shown). Thus, the crosslinked protein seemed to be the sequence
identified in the data base as BRP44 (Q9D023-Figure 2D) a
phylogenetically well-conserved protein (Figure 3A), which is a
member of a small protein family that includes BRP44L, also
phylogentically conserved (Figure 3B).
BRP44 was cloned and expressed in Cos7 cells with a C-
terminal GFP tag or a 66His tag. The native protein and the GFP
fusion protein were co-localized and an overlay with Mitotracker
Red revealed that the BRP44 protein is exclusively localized in the
mitochondria of these cells (Figure 4A). Subcellular fractions from
cells that expressed the 66His tag BRP44 were subjected to
photoaffinity crosslinking resulting in both the native protein and
the larger his-tagged species being selectively crosslinked
(Figure 4B). In a separate set of experiments, solubilized drug-
affinity crosslinked (with MSDC-1101) mitochondria from
HEK293 cells stably expressing BRP44 with a C-terminal
66His-tag were immunoprecipitated with an antibody to 66His.
The resulting autoradiogram (Figure 4C) demonstrated that the
crossked protein was precipitated while no labeled proteins were
precipitated from the wild type cells. This precipitated both the
radiolabled 66His-tagged BRP44 as well as other proteins in the
complex, including the native BRP44 and family member BRP44-
Like (demonstrated by Western blots and mass spectrometry, not
shown). These data provide strong evidence that BRP44 is the
mitochondrial protein that is crosslinked by the TZD photoprobe.
Given the phylogenic conservation of BRP44 (Figure 3A) and
the genetic tractability of a model organism, we evaluated whether
the Drosophila ortholog would show an interaction with the TZD
probe. As shown in Figure 5A, the TZD photoprobe specifically
Figure 1. Selective crosslinking with photo affinity probe. (A) Mitochondrial membranes (20 mg) from rat liver were incubated with the
iodinated (125I) photo-probe (MSDC-1101) in the absence of any competing compound (lane 1); in the presence of 25 mM MSDC-0160 (lane 2); in the
presence of 25 mM MSDC-0602 (lane 3); or in the presence of 25 mM MSDC-1473 (lane 4). Following exposure to UV light, samples were separated on
one dimensional SDS-PAGE and the dried gel was exposed to X-ray film. (B) Active TZDs, but not MSDC-1473, produce a dose-dependent increase in
UCP1 as detected on Western blots from mouse BAT progenitor cells. The abscissa shows drug concentration (mM). The inset on the top of this figure
shows a representative Western blot of the increase in UCP1 protein in cells treated with an active TZD (pioglitazone). The data below the blot show
the dose dependent increases observed in a representative experiment from a scan of the Western blots (arbitrary units, Mean and SE; N= 3). (C) Liver
mitochondrial fractions from wild type or mitoNEET null mice [11] were crosslinked as in A without (2) or with (+) 25 mM MSDC-0160. The top figure
is the resulting autoradiogram and the bottom is the Western blot for mitoNEET. (D) Mouse liver mitochondria were fractionated to generate
fractions for outer membrane (OM), inter membrane space (IMS), inner membrane (IMM), and matrix. Total protein (10 mg) from each fraction was
crosslinked as in A. The autoradiogram is shown at the top and a stain for total protein for the same 4 mitochondrial subfractions is shown below.
doi:10.1371/journal.pone.0061551.g001
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crosslinked a protein in crude mitochondrial pellets from both
larvae and adult flies. This is the expected size for the Drosophila
BRP44 ortholog, CG9399, which has an N-terminal extension
relative to the murine and human orthologs (Figure 3A). Database
searches identified four additional Drosophila proteins with signif-
icant sequence homology and fly lines with RNAi-mediated
knockdown of these genes were obtained. As predicted from
analyses of these sequences, the knockdown of CG9399 (gene 1,
Figure 5B) reduced the level of crosslinking in two fly lines.
Knockdown of CG9396, CG32382, or CG16790 had no effect on
the crosslinking, however, the knockdown of a CG14290, which
was predicted to code for the BRP44 Like ortholog (Figure 5B,
lanes labeled 4) also reduced the crosslinking. The BRP44 Like
protein is also well-conserved (Figure 3B). This result suggests that
these two proteins might function together to create the binding
site recognized by the TZDs. Antibodies were made to both
Figure 2. Crosslinked protein is BRP44. (A) Blue Native electrophoresis of crosslinked proteins showing the stain pattern (left) and the
corresponding autoradiogram image for the specifically crosslinked protein (without, ‘‘2’’on the left and with MSDC-0160 competition, ‘‘+’’, on the
right). The,150 kDa band is marked by the arrow. (B) Second dimension SDS separation of Blue Native gel without (left) and with (right) MSDC-0160
competition. Upper figures are silver stained images of the gels and lower figures are corresponding autoradiograms. Areas of interest are marked by
the yellow arrows. (C) Expanded view of silver-stained images showing the three areas submitted for MS/MS analysis followed by the respective
trypsin peptide sequences. These peptides (shown also in red, bottom frame D) identify BRP44 (Q9D023).
doi:10.1371/journal.pone.0061551.g002
Figure 3. BRP44 family. Upper panel (A) is the multiple species sequence alignment of BRP44 and lower panel (B) shows the multiple species
alignments for the family member protein BRP44L. Shaded amino acids show identical amino acids as compared to the human sequences.
doi:10.1371/journal.pone.0061551.g003
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proteins and utilized in Western blots to confirm the knock down
of the proteins (Figure 5C). These data demonstrate that the
knockdown of the expression of CG14290 protein (the BRP44
Like ortholog) also reduced the protein levels of CG9399 (BRP44
ortholog), which could explain the reduced crosslinking of the
CG9399 protein with the knockdown of the expression of either
gene.
Figure 4. Expressed BRP44 goes to mitochondrion and is crosslinked selectively by the TZD probe. (A) Upper frame: C-terminally-
tagged GFP BRP44 (green) in Cos7 cells is co-localized with endogenous BRP44 (red). Lower frame: C-terminally tagged 66His BRP44 (green) is co-
localized with Mitotracker Red confirming the mitochondrial localization. (B) A sequence encoding BRP44 C-terminally tagged with six histidine
residues was transiently expressed in HEK293 cells. Subcellular fractions were prepared (P1, crude nuclear fraction; P2, crude mitochondrial fraction;
S2, post mitochondrial fraction) and incubated with the radiolabeled photo-probe in the presence or absence of 25 mM MSDC-0160 as indicated.
Samples were subjected to one dimensional SDS-PAGE and the dried gel was exposed to X-ray film. The red arrows point to the image of the
selectively crosslinked native and C-terminal extension proteins. (C) Crosslinked BRP44 66His is selectively immunoprecipitated by antibodies to
66His. Membranes from HEK293 cells stably transfected with BRP44 66His (right lanes, 6 His) or non transfected cells (left lanes, control) were
crosslinked with or without competition with MSDC-0160 as in B. The membranes, all of which contained the specifically crosslinked band as shown
in B, were then solubilized and immunoprecipitation was carried out with anti-His agarose beads. The resulting pellets were solubilized and
submitted to SDS-PAGE. The corresponding autoradiogram is shown demonstrating that the radioactive band is only precipitated by anti-His tag in
the tissue from the cells expressing His-6 BRP44.
doi:10.1371/journal.pone.0061551.g004
Figure 5. Crosslinking of the Drosophila ortholog in wild type and knockdown lines. (A) Wild-type larvae and adult flies were homogenized
and mitochondrial pellets were crosslinked with and without the addition of MSDC-0160 as in figure 1. The autoradiograms of the resulting image of
the specifically crosslinked proteins are shown for the flies on the left side compared to mouse liver in the lane on the right. (B) Fly stocks carrying
RNAi constructs were crossed to Act-GAL4 driver and progeny tissues were processed and crosslinked as described in the text. Lanes marked ‘‘1’’ were
from knockdowns of CG9399, lanes marked ‘‘4’’ were from knockdowns of CG14290, the other lanes were either unrelated genes or control strains.
Two separate knockdown lines are represented. The complete list of the strains is shown in the text. Red arrows indicate reduced crosslinking of the
specific CG9399 protein (BRP44 ortholog). (C) Membrane samples from CG9399 and CG14290 KD as in B were subjected to Western blot analysis for
either the CG9399 (left) or CG14290 protein (right).
doi:10.1371/journal.pone.0061551.g005
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Mechanistic Evaluation of Pyruvate Metabolism
Bricker et al. [11] provided evidence that Mpc1 (BRP44L) may
be the site of interaction of the potent pyruvate transport inhibitor
a-cyannocinnamate analog, UK-5099. This conclusion was based
on a yeast mutant of Mpc1 that is no longer responsive to
inhibition by UK-5099. Adding UK-5099 to the assay, as was seen
with active TZDs, prevents the crosslinking of BRP44 (Mpc2) by
the TZD probe (Figure 6A), confirming that these two classes of
compounds bind in close proximity and suggesting that insulin
sensitizing TZDs might modulate pyruvate utilization.
Having shown previously that TZDs have demonstrable effects
on isolated BAT cells [16,18], and now suspecting that this may
involve an effect on pyruvate metabolism, we asked whether these
compounds could modify the entry of carbon into acetyl CoA in
these cells. Carbon flow into acetyl CoA was monitored by the
incorporation of 13C-glucose into acetyl CoA. As expected, the
addition of UK-5099, the potent inhibitor of pyruvate into the
mitochondrion, potently blocked the influx of heavy carbon into
acetyl CoA (Figure 6B). Treatment with MSDC-0602 resulted in a
biphasic change in the incorporation of the heavy label into acetyl
CoA. Whereas higher concentrations of MSDC-0602 inhibited
incorporation, lower concentrations actually increased 13C incor-
poration into acetyl CoA. Pioglitazone, rosiglitazone, and MSDC-
0160 have similar effects as observed with MSDC-0602, while
MSDC-1473 was ineffective (Figure 6B and C)). Interestingly, the
non-TZD insulin sensitizer MRL-24, a compound which also
binds to PPARc without directly activating it [19], inhibited
carbon flow into acetyl CoA under these conditions (Figure 6B).
We have also found that MRL-24 also increases UCP1 in BAT
cells and competes for crosslinking of Mpc2 (data not shown).
To determine whether simply reducing pyruvate flux would
mimic TZD action to increase UCP1 expression in brown fat
progenitor cells as shown in Figure 1B, we evaluated the effects of
UK-5099 under these conditions. The addition of increasing
concentrations of UK-5099 to BAT progenitor cells also resulted
in an increase in UCP1 content, however, in spite of the fact that it
was more potent at inhibiting pyruvate incorporation, much
higher concentrations were required than for the TZD to increase
expression of UCP1 (Figure 6D), suggesting that a simple
reduction in pyruvate transport is not the mechanism that
regulates the expression of UCP1 under these conditions.
Effect of knockdown of Mpc proteins on pharmacology
in flies
Growing Drosophila on a high sucrose medium produces a
model of insulin resistance which can be directly demonstrated on
insulin signaling in larvae [15]. As shown in Figure 7A, larvae
grown on high sucrose matrix demonstrated insulin resistance in
terms of the inability of insulin to acutely increase the phosphor-
ylation of AKT. Under these conditions, treatment of the larvae
with MSDC-0160 increased insulin action in this respect, while the
inactive analog MSDC-1473 was ineffective (Figure 7B). We
Figure 6. BPR44 and BRP44L are involved in pyruvate transport. (A) UK5099 structure and effect of adding either 25 mM MSDC-0160 (lane 2)
or UK5099 (lane 3) on crosslinking of BRP44 (Mpc2). Lane 1 is the DMSO control. (B) Incubation of mouse BAT cells with UK5099 effectively limits
carbon flow from U-13C glucose into acetyl CoA (red line) while MSDC-0602 has a biphasic dose response. The non TZD insulin sensitizer MRL-24 also
modulated flow of carbon into acetyl CoA under these conditions. Data are the ratio of Acetyl CoA (13C/12C) derived from U-13C glucose following a
2 hour pre-incubation and a 15 minute flux at 37C (n = 3; mean and SE; representative of 3 experiments) as described in the Methods. (C) A separate
experiment similar to that shown in B with other TZDs. (D) BAT progenitor cells were incubated with the indicated concentrations of UK5099 with (+)
or without (2) 3 mM MSDC-0160 for 5 days. Cells were lysed and Western blots were conducted for UCP1 as in Figure 1B.
doi:10.1371/journal.pone.0061551.g006
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evaluated the effects of knockdown of the mTOT proteins on the
response to high sucrose feeding and insulin sensitizer treatment in
this model by evaluating the expression of the genome under these
conditions. Expression of 58 genes was increased by the drug
treatment and expression of 26 genes was reduced by drug
treatment. Importantly, all of these effects were lost upon the
knockdown of the Mpc1 ortholog, CG14290, which reduces the
expression of both proteins (Figure 5C), suggesting that this
complex is involved in the drug action. Figure 7C shows an
example of a subset of these genes expressed relative to the
differences from the high sucrose control.
Discussion
In this report, we show that the insulin sensitizing TZDs have a
recognition site in the inner mitochondrial membrane that is
comprised of a recently identified protein complex involved in
mitochondrial pyruvate import. We have called this complex
mTOT (mitochondrial target of thiazolidinones). The key
members of mTOT, Mpc1 (BRP44 Like) and Mpc2 (BRP44),
are highly conserved proteins involved in facilitated pyruvate
transport into the mitochondrial matrix [11,12]. This complex
could provide a link between mitochondrial pyruvate metabolism
and the efficacy of this class of drugs. Indeed, active insulin
sensitizers including pioglitazone and rosiglitazone can directly
inhibit pyruvate oxidation and this has also been shown in a
variety of intact and permeabilized cells (Divakaruni, unpub-
lished). However the data from figure 6 do not support the
hypothesis that the pharmacology is tied directly to limiting
pyruvate metabolism per se. In fact, it appears that in the intact cells
the effects of the compounds on pyruvate flux are complicated and
include either an increase or decrease depending on the
concentrations of the compounds. Moreover, UK-5099, which is
a potent inhibitor of pyruvate flux, did not increase the expression
of UCP1 at concentrations at which this inhibition was observed.
It will be important to understand more about the other proteins
Figure 7. Insulin sensitizer effects in wild type and knockdown flies. (A) Acute insulin action was measured in inverted larvae in the absence
(2) or presence (+) of 2 mM recombinant insulin. The larvae were either grown under control conditions (left) or in the presence of high sucrose
(right). Representative Western blots are shown below and the calculated areas are shown above for pAKT (left side) or total AKT (right side)
normalized to actin in the absence (open bars) or presence of insulin (upper bars). An unpaired, two-tailed t-test was used to derive p-values. Error
bars are 6 SE (N= 3). (B) Effect of incubation with DMSO, MSDC-1473 or MSDC-0160 on the amount of insulin-stimulated phosphorylation of AKT
under the high sucrose conditions (detected and analyzed as in A; mean and SE, N = 3). (C) Wild-type female flies or flies with knockdown of CG14290
(as in Figure 5) were raised on a 0.75M sucrose matrix and aged for 7 days with or without MSDC-0160 added to the matrix. RNA from flies grown
under these conditions was extracted and full genome expression analysis was performed using the Agilent system. Conditions in the presence of the
high sugar included control flies in addition to knock down of CG14290 (line 15858). MSDC-0160 was provided to either control or line 15859
knockdown flies. The data shown reflect changes that were more than 1.5 fold different and t-test value ,9E-03 relative to the high sucrose DMSO
control in terms of increase (green) or decrease (red). The list of genes, along with the mammalian ortholog names, are shown on the left in the case
of where the expression was decreased in the presence of high sucrose and thus increased with the treatment of MSDC-0160 and on the right for the
transcripts that were increased in the presence of high sucrose and thus reduced with the treatment with MSDC-0160. All MSDC-0160-induced
changes were lost in the knockdown strain.
doi:10.1371/journal.pone.0061551.g007
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associated with the newly identified mitochondrial complex and to
further define the exact effects on insulin sensitizers of both TZD
and non TZD classes on the functions of these proteins. The
delineation of the mechanisms by which insulin sensitizers
modulate metabolism through this interaction may provide insight
into the pleiotropic pharmacology of these compounds. These
studies may define how post-transcriptional regulation is orches-
trated in response to nutritional status and thus provide insight
into the potential to treat diseases associated with dysfunctional
metabolism. Dysfunctional metabolism is thought to play a role in
cancer, neurodegeneration, chronic inflammation, as well as
diabetes. Definition of these molecular interactions may also
inform design of the next generation of therapeutic agents. This
newly identified drug target places insulin sensitizers at the
crossroads of carbohydrate, lipid, and amino acid metabolism.
Interestingly, alterations in various features of cellular metabolism
including fatty acid and amino acid metabolism, are known to be
predictors of insulin resistance and to respond to anti-diabetic
treatment [20].
Up to the present time, most insulin sensitizer discovery
programs have focused on the ability of TZDs and other
molecules to bind to and activate the transcription factor PPARc.
This transcription factor is a potent regulator of adipocyte
differentiation and many of the original TZD analogs were able
to activate this transcription factor to various degrees [21].
Although many active molecules were found by modeling
interactions with this target, none of these efforts have yielded a
drug that could meet regulatory approval, primarily as a result of
unacceptable side effects [4]. Recently, rosiglitazone, the most
potent PPARc activator of the original compounds approved, has
essentially been removed from clinical use because of potential
cardiovascular side effects [5]. Interestingly, the much weaker
PPARc agonist, pioglitazone remains of clinical use [3]. We had
previously suggested that activation of PPARc is not needed for
insulin-sensitizing pharmacology [4], but a plausible alternative
mechanistic target has not been provided until this report.
Chen et al. [6] demonstrated that novel PPARc-sparing
molecules have similar pharmacology as the first generation
insulin sensitizers, rosiglitazone and pioglitazone. In addition, we
found that all of the compounds, including rosiglitazone, had clear
direct effects on hepatocytes that are completely independent of
PPARc. The studies presented here in Drosophilia suggest that the
insulin sensitizing pharmacology may require the action of this
newly identified mitochondrial complex. Thus, the ability of drug
treatment to return the gene expression profile in the presence of
high sucrose to the low sucrose control levels was lost upon
knockdown of the Mpc proteins (Figure 7C). However, at this
time, we do not know the extent to which insulin sensitizing effects
are mediated through the mTOT complex in mammals. Firm
conclusions await the characterization of genetically modified
mice. The critical importance of Mpc1 and Mpc2 expression (both
total amount and stoichiometry of the two proteins) to the cell/
organism is readily seen in that over-expression in mammalian
cells results in cell death (unpublished observations and [22]) while
ablation of Mpc2 in mice is embryonic lethal (E11, E12) at a time
when mitochondrial function becomes critical for continued
development. Thus, studies involving tissue specific, conditional
ablation or over-expression will be required to fully characterize
the role of these proteins in the regulation of cellular metabolism.
The mitoNEET protein was the first mitochondrial membrane
protein identified as a potential mitochondrial insulin sensitizer
target based on early studies using the pioglitazone-based
photoaffinity probe [9]. This protein has proven of interest to
many interested in mitochondrial metabolism [14,23,24] and work
with the mitoNEET crystal structure has even suggested a
potential pioglitazone binding site [24]. However, we have
concluded that mitoNEET is not the primary mitochondrial
TZD target because we were able to demonstrate photoaffinity
crosslinking in liver mitochondrial membranes from mice that
were null for expression of mitoNEET (Figure 1). Interestingly,
recent work demonstrates that as a component of the outer
mitochondrial membrane, mitoNEET can directly bind NADPH
[25] and that it plays an important role in the regulation of
mitochondrial function and regulation of adiponectin production
[26]. An exploration of a possible association of mitoNEET with
the mTOT complex is warranted.
In conclusion, this paper identifies mTOT, a mitochondrial
target of thiazolidinediones, as a mitochondrial membrane
complex involved with pyruvate transport. The cell experiments
with 13C incorporation into acetyl CoA suggest that the TZDs
modulate pyruvate entry into the TCA cycle, however it is not
clear from our studies that direct changes in pyruvate flux can itself
explain the pharmacology. Thus, the effects of the insulin
sensitizers are not mimicked by concentrations of UK-5099 that
inhibit pyruvate flux. It is possible that drug interaction may
provide a more general signal controlling cell function, especially
insulin sensitivity, perhaps by alteration of redox signaling
mechanisms. However, Satapati et al. have shown that over
activation of the TCA cycle is part of the pathology associated with
over nutrition and hepatic insulin resistance [27] and this may also
contribute to non-alcoholic fatty liver disease [28]. Insulin
sensitizers may restore some functions by selectively returning
the balance of carbon flow under these conditions. It is unknown
at this time whether there are additional functions of Mpc1
(BRP44 Like) and Mpc2 (BRP44) or whether other members of
mTOT, the protein complex that contains them, could play
important roles in tissue-specific regulation of metabolism and cell
function. For example, this complex may regulate mitochondrial
fatty acid synthesis or reactive oxygen signals in lower organisms
[12], but this has not been examined in mammals. In any event, it
is clear these proteins sit at the central control point for regulation
of metabolism [29]. The current studies provide background and
initial tools for detailed study of this protein complex in metabolic
disease and also suggest a new approach for the discovery and
development of potentially more useful and novel insulin
sensitizers. While this manuscript was in review, studies on direct
effects of TZDs on pyruvate metabolism were published [30].
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